Activaero raises €10.7m for breathing device development

The company will use the funding to develop its platform inhalation device technology and strengthen business development. Activaero currently has two products on the market, AKITA, a patient-controlled breathing system with a smartcard that records the patient dosing parameters, and Watchhaler, a handheld delivery system for children.  

Activaero also has a range of technologies for the controlled delivery of inhaled therapeutics in the clinical trial setting, as well as offering consultancy services for the development of inhaled delivery systems and logistics on clinical trials.

Activaero CEO Gerhard Scheuch said, “Securing venture capital support for Activaero is important for our strategy to further increase visibility and awareness within the pharmaceutical industry and provide superior products and technologies to our collaboration partners. The development and commercialisation of our products and technology is now securely funded going forward.”

BioMed Partners provides private equity and mezzanine financing to seed- and mid-stage healthcare and life science companies, with a focus on pharmaceuticals, biotechnology, diagnostics and medical technology.

Copyright © 2009 AltAssets